Lundbeck to announce new data across neurology portfolio at AAN 2026
Lundbeck announced that new data across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18–22 in Chicago, U.S.
The presentations span migraine, developmental and epileptic encephalopathies (DEEs) and multiple system atrophy (MSA), and underscore Lundbeck’s focus on advancing brain disease treatments where there is significant unmet need.
Among the highlights are new Phase 1 data on bocunebart, a potential first-in-class investigational monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide (PACAP), a pathway distinct from the calcitonin gene-related peptide (CGRP) mechanism targeted by current preventive migraine therapies. The analysis evaluates the safety and tolerability of bocunebart when administered alongside a gepant, a class of oral CGRP receptor antagonist commonly used in migraine management.
Lundbeck will also present data on eptinezumab, an intravenous anti-CGRP preventive treatment for migraine. These include a post-hoc analysis from DELIVER, a randomized Phase 3b trial investigating headache-free periods and patient-reported outcomes in individuals whose migraine had not responded to multiple prior preventive treatments. New interim findings from the ongoing 12-month INFUSE real-world study will report six-month outcomes, including data on migraine-related cognitive symptoms, in patients who had experienced failures with at least one prior anti-CGRP preventive treatment.
In rare childhood-onset epilepsy, Lundbeck will present primary 12-month results from the open-label extension of the Phase 1b/2a PACIFIC trial evaluating bexicaserin, an investigational selective 5-HT2C receptor superagonist being studied for the treatment of seizures in DEEs, including Dravet syndrome and Lennox-Gastaut syndrome.
Separately, findings will be presented from a Delphi consensus study in MSA, a rare neurodegenerative movement disorder with no currently approved treatment. The Delphi panel examined the appropriateness of expressing treatment effect as a percentage-wise slowing of clinical progression on the Unified Multiple System Atrophy Rating Scale (UMSARS), and the threshold for clinical meaningfulness.
Together, these data highlight Lundbeck’s expanding neurology pipeline and its continued commitment to advancing treatments for serious brain diseases.
View details of Lundbeck presentations at AAN 2026 HERE.
